Loading organizations...
§ Venture Capital · One Broadway, 9th Floor, Cambridge, MA 02142, USA
A fund entity. Details regarding its specific operations, business model, sectors, and market focus are not publicly available.
Ample Plus Fund operates as a venture capital firm, strategically deploying capital into early-stage and growth-oriented companies. Specializing in healthcare and technology sectors, the fund identifies and supports innovative businesses poised for market disruption. Its approach involves rigorous due diligence and active portfolio management, fostering transformative solutions within its chosen industries.
The fund is a newly organized management investment company, structured as a limited partnership. While specific founding individuals are not publicly available, it was formed to capitalize on emergent opportunities across technology and healthcare. Registered in the Cayman Islands, its establishment created a dedicated vehicle for specialized sector investment.
Ample Plus Fund targets private companies within healthcare and technology verticals seeking capital for development, scaling, or market entry. Its vision centers on being a pivotal financial partner, enabling these enterprises to translate innovative concepts into market successes. The firm ultimately aims to generate substantial returns by nurturing the next generation of industry-leading companies.
Ample Plus Fund has 2 tracked investments across 2 companies. The latest tracked deal is $80.0M Series C in Cyteir Therapeutics in February 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Feb 1, 2021 | Cyteir Therapeutics | $80.0M Series C | Derek Dirocco | Advanced Technology Ventures, Aisling Capital, Dolby Family Ventures, Novo Ventures, Venrock, Acuta Capital Partners, Ally Bridge Group, Avidity Partners, Caas Capital Management, Droia Ventures, Janus Henderson Investors, Lightstone Ventures, Osage University Partners |
| Jul 5, 2020 | Freeline | $120.0M Series C Extension | Eventide Asset Management, Thomas Dyrberg, Wellington Management | Acorn Bioventures, Cowen Healthcare Investments |